Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

The national capital has reported an "isolated" case of Japanese Encephalitis, official sources said on Thursday. All public health measures have been instituted as per the National Centre for Vector Borne Diseases Control (NCVBDC) guidelines, the sources said, adding there was no cause for concern. Referring to an order issued by the Municipal Corporation of Delhi on Wednesday, the sources said that the 72-year-old man from west Delhi was admitted to the All India Institute of Medical Sciences on November 3 following chest pain. The patient was diabetic, had coronary artery disease, bilateral lower limb weakness and bowel and bladder incontinence, the source said. After the patient's blood sample was collected on November 6, he tested positive for Japanese Encephalitis. He was discharged on November 15, the sources said. According to the Integrated Disease Surveillance Programme data, in 2024, 1,548 Japanese Encephalitis cases were reported from 24 states and Union Territories, with 925 cases from Assam alone. The central government guidelines, two doses of the vaccine have been a part of the Universal Immunisation Programme since 2013. Adult <keyword id="24203625" type="General" weightage="20" keywordseo="Japanese-Encephalitis-vaccine" source="keywords">Japanese Encephalitis vaccine</keyword> has been introduced in high-burden states, sources said. "No outbreak of Japanese Encephalitis has been reported in Delhi in the past although occasional isolated cases have been reported from tertiary hospitals like AIIMS, Ram Manohar Lohia and Safdarjung among others - mostly from neighbouring states," a source said. While all public health measures have been instituted according to the NCVBDC guidelines, there is no cause for concern due to this isolated case of Japanese Encephalitis, the source said. The Japanese Encephalitis virus is normally carried by waterfowl and amplified in pigs from where it is accidentally transmitted to humans through the bite of infected culex mosquitoes. The infection may result in febrile illness and in a small proportion of cases cause neurological illness and may result in death, he said. There is no specific treatment for Japanese Encephalitis and there is no human-to-human transmission of the virus, the source said. SEE ALSO:<a href="https://www.businessinsider.in/business/auto/news/honda-activa-e-and-qc1-electric-scooters-unveiled-in-india-to-go-on-sale-in-2025/articleshow/115725242.cms" target="_self"></a> <a href="https://www.businessinsider.in/business/auto/news/honda-activa-e-and-qc1-electric-scooters-unveiled-in-india-to-go-on-sale-in-2025/articleshow/115725242.cms" target="_self">Honda Activa e and QC1 electric scooters unveiled in India, to go on sale in 2025</a><a href="https://www.businessinsider.in/tech/news/indias-pc-market-reaches-new-high-with-4-49-million-shipments-in-q3-2024/articleshow/115719599.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/news/indias-pc-market-reaches-new-high-with-4-49-million-shipments-in-q3-2024/articleshow/115719599.cms" target="_blank">India’s PC market reaches new high with 4.49 million shipments in Q3 2024</a><a href="https://www.businessinsider.in/tech/mobile/news/realme-gt-7-pro-with-snapdragon-8-elite-chipset-launched-starting-at-59999/articleshow/115689685.cms" target="_blank"></a> <a href="https://www.businessinsider.in/tech/mobile/news/realme-gt-7-pro-with-snapdragon-8-elite-chipset-launched-starting-at-59999/articleshow/115689685.cms" target="_blank">Realme GT 7 Pro with Snapdragon 8 Elite chipset launched starting at ₹59,999</a>

Delhi reports 'isolated' case of Japanese Encephalitis

<keyword id="13486" type="General" weightage="100" keywordseo="vietnam" source="Orion">Vietnam</keyword> has reported about 260,000 cases of dengue fever infections and 102 deaths so far this year, the <keyword id="210071" type="General" weightage="80" keywordseo="ministry-of-health" source="Orion">Ministry of Health</keyword> said Friday. The number of infections and fatalities grew nearly five times from the same period in 2021, the <keyword id="48413" type="General" weightage="80" keywordseo="ministry" source="Orion">Ministry</keyword> said, adding that "major outbreaks" are likely to occur in many provinces and cities in November and December, reports <keyword id="106387" type="General" weightage="80" keywordseo="xinhua-news-agency" source="Orion">Xinhua news agency</keyword>. Ho Chi Minh City is still the hotspot with nearly 70,000 cases and 29 deaths. The capital Hanoi has seen more than 8,000 cases with 12 deaths. Besides dengue, Vietnam has also witnessed the complicated development of other diseases recently. In the northern <keyword id="15371776" type="General" weightage="80" keywordseo="bac-kan" source="Orion">Bac Kan</keyword> province, more than 700 primary school students have come down with the mysterious flu, and among them, an eight-year-old child has died. Among seven samples sent for testing, five came back positive for the influenza B strain, while the others came back negative. In Hanoi, there is an increase in infections of some diseases including 1,543 cases of hand, foot and mouth disease, 11 cases of tetanus and four cases of Japanese encephalitis. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/african-countries-have-reported-6883-monkeypox-cases-173-deaths-in-2022/articleshow/95135227.cms">African countries have reported 6,883 Monkeypox cases, 173 deaths in 2022</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/delhis-air-quality-still-very-poor/articleshow/95139154.cms">Delhi's air quality still 'very poor'</a>

Vietnam reports 260,000 dengue cases, 102 deaths

New Delhi, Apr 29 () The Indian Institute of Technology (IIT), Guwahati and Ahmedabad-based pharmaceutical company Hester Biosciences Limited have come together for developing a vaccine against coronavirus. According to officials, the vaccine is expected to be ready by the end of this year to start animal studies and the work is currently in its early stage of development. The team at IIT Guwahati headed by Sachin Kumar, an associate professor at the Department of Biosciences and Bioengineering, has generated the "recombinant avian paramyxovirus-1 based vaccine flatform" for classical swine fever and japanese encephalitis. The agreement between the institute and the pharmaceutical company was signed on April 15. The role of the institute will be to produce the recombinant vaccine candidate. "The vaccine will be based on recombinant avian paramyxovirus based vector platform. The recombinant avian paramyxovirus-1 will be used to express the immunogenic protein of SARS-CoV-2. The recombinant avian paramyxovirus-1 expressing the SARS-CoV-2 protein could be used as a vaccine candidate for further study. "It is too early to comment on the efficacy and immunogenicity of the vaccine, however, we will be able to reveal more details about this vaccine after the results of animal studies are obtained," Kumar said.According to Kumar, the avian paramyxovirus-1 has been explored as a vaccine vector for various animals and human pathogens. "The avian paramyxovirus-1 has been used to express the immunogenic protein of human pathogens such as HIV, avian influenza virus, human parainfluenza virus, SARS-CoV. Similarly, it has also been explored as a vaccine vector for animal pathogens such as infectious bursal disease virus, infectious laryngotracheitis virus, bovine herpes virus, Nipah virus," he added.Elaborating on the collaboration and role of Hester Biosciences Limited, its CEO and MD Rajiv Gandhi, said, "In the current pandemic situation of COVID-19, the world is looking at developing preventive and curative measures to safeguard mankind. We have collaborated to develop and manufacture a recombinant vaccine against COVID-19 disease as a preventive measure. Hester's involvement would be from master seed development up to release of the commercial vaccine." Around the world, confirmed infections of coronavirus stood at more than 3.1 million - including 1 million in the US - and the confirmed global death toll topped 217,000, according to a tally by Johns Hopkins University. In India, the death toll due to COVID-19 rose to 1,007 and the number of cases climbed to 31,332 in the country on Wednesday, according to the Union Health Ministry. The number of active COVID-19 cases stood at 22,629, while 7,695 people have recovered, and one patient has migrated, the ministry said. GJS AAR

IIT Guwahati, pharma company Hester Biosciences come together to develop COVID-19 vaccine

<ul><li>The Indian Council of Medical Research (<keyword id="6364396" type="UNKNOWN" weightage="20" keywordseo="ICMR">ICMR</keyword>) is working to launch the first made-in-India <keyword id="8624004" type="UNKNOWN" weightage="20" keywordseo="coronavirus-vaccine">coronavirus vaccine</keyword> by August 15 in partnership with Bharat Biotech International Limited (BBIL).</li><li>The indigenous COVID-19 vaccine ‘Covaxin’ is currently under clinical trials. </li><li>The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of ‘COVAXIN’.</li></ul>While the world still awaits a vaccine for coronavirus and trials are underway, the Indian Council of Medical Research (ICMR) has set a deadline for as soon as August 15 to make its vaccine – Covaxin available for all. Even the Oxford COVID-19 vaccine may hit the Indian market <a href="https://www.businessinsider.in/science/health/news/oxford-covid-19-vaccine-may-hit-the-indian-market-by-the-end-of-the-year-if-successful-says-ceo-of-worlds-largest-vaccine-manufacturer/articleshow/76763833.cms">only by the end of the year</a>, if successful. ICMR’s indigenous COVID-19 vaccine (BBV152 COVID vaccine) or ‘Covaxin’ is currently under clinical trials. ICMR is working in partnership with Bharat Biotech International Limited (BBIL) to develop this vaccine. According to reports, this is one of the top priority projects which is being monitored at the topmost level of the government. If successful, this will be the first indigenous vaccine being developed by India. “The vaccine is being derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology, Pune. ICMR and BBIL are jointly working for the preclinical as well as clinical development of this vaccine,” ICMR Director General Balram Bhargava wrote in a letter to the heads of the selected institutions. Bharat Biotech’s track record in developing vero cell culture platform technologies has been proven in several vaccines for Polio, Rabies, Rotavirus, Japanese Encephalitis, Chikungunya and Zika. “It is envisaged to launch the vaccine for public health use latest by August 15, 2020, after completion of all clinical trials. BBIL is working expeditiously to meet the target. However, the final outcome will depend on the cooperation of all clinical trial sites involved in this project,” reads the letter dated July 2. Informing the institutions of their selection as clinical trials sites for the vaccine the IMCR director-general strictly advised them to fast track all approvals related to the initiation of the clinical trial and ensure that the subject enrollment is initiated no later July 7, 2020. ICMR’s COVID-19 vaccine doesn’t sound convincing to experts However, the letter of ICMR received much criticism from experts on social media for its tone. Some even questioned ICMR for deciding the efficacy of the vaccine even before the clinical trials. <div type="twitter" handle="AnantBhan" handlename="Anant Bhan" image="http://pbs.twimg.com/profile_images/1017714876964171776/_Qri-OTb_normal.jpg" favoritecount="1510" retweetcount="904" status="This is a letter which has been sent out by the ICMR DG yesterday. Now that multiple folks have confirmed genuinene… https://t.co/uaj5aMgUyV" createdat="1593748686000" id="1278900800530472960"></div> Earlier in May, <a href="https://www.businessinsider.in/science/health/news/biocon-chairperson-kiran-mazumdar-shaw-says-indias-covid-19-vaccines-will-enter-clinical-trial-in-9-months/articleshow/75591805.cms">Kiran Mazumdar Shaw, founder and executive chairperson at Biocon told Business Insider</a> that vaccine development takes a lot of time because several phases are involved in it. In the first phase, a dose escalation is done to see what the ideal dose for an optimal immune response is. In the second phase, it is tested if the immune response can be done in all age groups. This is important as the first phase is conducted with young, healthy volunteers who are at minimal risk. In the third phase, the vaccine is given to a larger population to ensure that the same immune response is given by everyone who is vaccinated. “One of the most important things of this phase is to check how long the immunity stays. This allows us to determine how often a person will have to get revaccinated,” Shaw further noted. Speaking about the production capacity, Shaw said that even after the vaccine is approved, India may not be able to produce more than 10-20 million doses in the first year, which is a negligible amount considering India’s population. ICMR selects 12 institutes for clinical trial The ICMR has selected 12 institutes, including one from Odisha, for the clinical trial of ‘COVAXIN’. Bhubaneswar-based Institute of Medical Sciences and SUM Hospital under the SOA Deemed to be University, has been chosen by the Indian Council for Medical Research (ICMR) for undertaking human clinical trials of India’s first coronavirus vaccine. In view of the public health emergency due to COVID-19 pandemic and urgency to launch the vaccine, the selected institutes are strictly advised to fast track all approvals related to the initiation of the clinical trial and ensure that the subject enrolment is initiated during the first week of July. Apart from IMS and SUM Hospital, the other institutes selected for the clinical trial are located in Visakhapatnam, Rohtak, New Delhi, Patna, Belgaum (Karnataka), Nagpur, Gorakhpur, Kattankulathur (Tamil Nadu), Hyderabad, Arya Nagar, Kanpur (Uttar Pradesh) and Goa. SEE ALSO:<a href="https://www.businessinsider.in/india/news/these-are-the-companies-manufacturing-covid-19-remdesivir-medicine-in-india/articleshow/76747405.cms" data-type="tilCustomLink"> These are the companies manufacturing COVID-19 drug Remdesivir in India</a> <a href="https://www.businessinsider.in/india/news/pm-narendra-modi-reaches-leh-with-general-bipin-rawat-and-general-mm-naravane-after-the-galwan-valley-standoff-with-china/articleshow/76763940.cms" data-type="tilCustomLink">PM Narendra Modi visits Ladakh – two weeks after the Galwan valley standoff with China</a>

You Searched For "Japanese Encephalitis Delhi" and got 4 results

Delhi reports 'isolated' case of Japanese Encephalitis

PTI

Vietnam reports 260,000 dengue cases, 102 deaths

IANS

IIT Guwahati, pharma company Hester Biosciences come together to develop COVID-19 vaccine

PTI

India wants a COVID-19 vaccine by August 15 at the risk of rushing trials and approvals

Navdeep Yadav

Popular Keywords

Buying Guides